The following results were estimated from the review. (Range or 95% confidence interval are given in brackets).
The difference in HbA1c change from baseline at week 52: orlistat versus control (%) was -0.37 (-0.38 to -0.36).
The persistence of HbA1c effect following year 1 was 3 (1 - 3).
The rate of all complications per 1,000 person-years was 74.5 (62.6 - 88.8).
The rate of myocardial infarction (MI) per 1,000 person years was 30.0 (22.9 - 39.4).
The rate of stroke per 1,000 person years was 7.4 (4.5 - 11.9).
The rate of peripheral vascular disease (PVD) per 1,000 person years was 4.0 (1.8 - 9.0).
The rate of macrovascular disease per 1,000 person years was 22.8 (16.7 - 31.3).
The rate of heart failure per 1,000 person years was 4.4 (2.4 - 8.2).
The rate of cataract extraction per 1,000 person years was 6.9 (4.4 - 10.8).
The rate of diabetes-related deaths per 1,000 person years was 23.5 (17.2 - 32.0).
The rate of all-cause mortality per 1,000 person years was 31.8 (24.7 - 40.8).
The relative risk reduction of MI per 1% mean updated HbA1c (%) was 14.0 (8.0 - 21.0).
The relative risk reduction of stroke per 1% mean updated HbA1c (%) was 12.0 (1.0 - 21.0).
The relative risk reduction of PVD per 1% mean updated HbA1c (%) was 43.0 (31.0 - 53.0).
The relative risk reduction of microvascular disease per 1% mean updated HbA1c (%) was 37.0 (33.0 - 41.0).
The relative risk reduction of heart failure per 1% mean updated HbA1c (%) was 16.0 (3.0 - 26.0).
The relative risk reduction of cataracts per 1% mean updated HbA1c (%) was 19.0 (11.0 - 26.0).
The relative risk reduction of MI per 0.9% raw annual HbA1c (%) was 16.0 (0.0 - 29.0).
The relative risk reduction of stroke per 0.9% raw annual HbA1c (%) was -11.0 (-49.0 - 19.0).
The relative risk reduction of PVD per 0.9% raw annual HbA1c (%) was 35.0 (-18.0 - 64.0).
The relative risk reduction of microvascular complications per 0.9% raw annual HbA1c (%) was 25.0 (7.0 - 45.0).
The relative risk reduction of heart failure per 0.9% raw annual HbA1c (%) was 9.0 (-35.0 - 39.0).
The relative risk reduction of cataracts per 0.9% raw annual HbA1c (%) was 24.0 (0.0 - 42.0).